Boston Scientific increases reserves for Guidant suits
243896
Boston Scientific Corp. has reserved another $101 million to defend itself against lawsuits over defibrillators made by Guidant Corp., the heart-device maker it acquired for $27 billion last year. The Natick medical-device company has set aside $485 million to pay for legal costs related to Guidant, it said in a filing this week, up from $384 million in ...
457592
Shares in British insurer Resolution  climbed more than 3 percent in early trade on Monday on hopes of a 5 billion pound ($10.2 billion) bid from rival Standard Life , backed by Swiss Re .
148143
Johnson & Johnson JNJ.N has sued   Boston Scientific BSX.N and Abbott Laboratories Inc. ABT.N,   seeking at least $5.5 billion in damages related to J&J's   failed bid to acquire medical device maker Guidant Corp.
374364
Boston Scientific Corp. wants to get deeper under your skin. Lawrence C. Best, its chief financial officer, says the company will make more than $2 billion worth of deals over the next two years, many of them in technologies that play a much more invasive medical role, compared to Boston Scientific's traditional products.
97019
Johnson &amp; Johnson is in advanced negotiations to acquire Guidant, an Indianapolis-based medical device maker, for more than $24 billion, executives close to the talks said Monday.
651779
Berkshire Hathaway discloses a few more stock purchases.
742004
Boston Scientific reported weaker quarterly earnings on higher expenses from its acquisition of the Guidant Corporation.
155100
Standard &amp; Poor's raised its outlook on Boston Scientific Corp. to positive from stable, citing its recovery of market share for its drug-coated Taxus cardiac stent after recalls that began in July. The debt rating agency said the upgrade reflects the Natick company's &quot;surprisingly rapid recovery&quot; of market share for Taxus, and its diverse product line. Last week, Boston Scientific ...
700879
The bond insurer is raising $1 billion in an effort to stay afloat.
121832
Prudential Plc, Britain&#39;s No. 2 insurer, plans to raise 1 billion pounds ($1.8 billion) by selling new stock to help fund a UK expansion and comply with European rules on capital reserves.
731230
The biotech mines extra value from its compound library.
239166
The U.S. government on Tuesday  proposed expanding Medicare coverage for costly, potentially  life-saving implanted heart devices, a decision expected to  benefit makers Guidant Corp., Medtronic Inc. and St. Jude  Medical Inc.
481790
MassDevelopment and Middlesex Savings Bank will issue a $1 million low-interest loan to Hyaluron Inc. The pharmaceutical biotechnology service company will use the funds to expand clean-room manufacturing space at its Burlington headquarters. It will also purchase back up systems for its electrical and mechanical infrastructure. Founded in 1999, Hyaluron provides aseptic manufacturing services. Sweeny joins insurance firm
253054
A jury in Texas has ruled that Boston Scientificâs drug-coated stents infringe a 1997 patent issued to a radiologist in Princeton, N.J., and has awarded the inventor $431 million in damages, Boston Scientific said Tuesday. The suit by the patent holder, Dr. Bruce N. Saffran, did not seek to halt sales of the stents.
517153
Boston Scientific Corp. yesterday revealed details about the experimental drug-coated stent it acquired when it bought Guidant Corp. this year. The device will be called Promus, and the Natick medical device maker expects to start selling it in 2008.
646222
The anticipated merger of Guidant Corp. and Johnson &amp; Johnson could give an unintended boost to Boston Scientific Corp. if Guidant's drug-coated stent launch is delayed, said analysts looking at the implications of a potential deal.
362793
Standard &amp; Poor&#39;s Equity Research lowered the price target for Boston Scientific (nyse: BSX - news - people ) to $41 from $44 and said the company&#39;s dispute with former partner Medinol will likely go to trial next year.